Anne M Pilaro - JoVE Visualize

Search research articles

Contact Us

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Privacy Policy

Policies

Search research articles

Contact Us

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Privacy Policy

Policies

Filters

Anne M Pilaro

Showing results (1-10 of 2) with videos related to

Pageof 1

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008

U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimensRuthann M Giusti, Kaushikkumar Shastri, Anne M Pilaro, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013

First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.

Pageof 1

Search research articles

Showing results (1-10 of 2) with videos related to

Sort By:

Pageof 1

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008

U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimensRuthann M Giusti, Kaushikkumar Shastri, Anne M Pilaro, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013

First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.

Pageof 1